With over 70,000 annual deaths, fentanyl overdose is the leading cause of death for Americans aged 18-45. In collaboration with Cessation Therapeutics, Dr. Vince Clinical Research (DVCR) led a First-in-Human trial to test a breakthrough anti-fentanyl antibody. Download our white paper to learn more about the challenges, solutions and results of this study.

Authors:

Bradley D. Vince, DO, CEO & Chief Medical Officer
Steven Hull, MD, FCCP, FAASM, Medical Director & Principal Investigator
Justin Couture, Director, Safety Operations